The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Distinct Antitumor Properties of a Type IV Collagen Domain Derived from Basement Membrane
Open accessAbstract
Vascular basement membrane is an important structural component of blood vessels. During angiogenesis this membrane undergoes many alterations and these changes are speculated to influence the formation of new capillaries. Type IV collagen is a major component of vascular basement membrane, and recently we identified a fragment of type IV collagen alpha2 chain with specific anti-angiogenic properties (Kamphaus, G. D., Colorado, P. C., Panka, D. J., Hopfer, H., Ramchandran, R., Torre, A., Maeshima, Y., Mier, J. W., Sukhatme, V. P., and Kalluri, R. (2000) J. Biol. Chem. 275, 1209-1215). In the present study we characterize two different antitumor activities associated with the noncollagenous 1 (NC1) domain of the alpha3 chain of type IV collagen. This domain was previously discovered to possess a C-terminal peptide sequence (amino acids 185-203) that inhibits melanoma cell proliferation (Han, J., Ohno, N., Pasco, S., Monboisse, J. C., Borel, J. P., and Kefalides, N. A. (1997) J. Biol. Chem. 272, 20395-20401). In the present study, we identify the anti-angiogenic capacity of this domain using several in vitro and in vivo assays. The alpha3(IV)NC1 inhibited in vivo neovascularization in matrigel plug assays and suppressed tumor growth of human renal cell carcinoma (786-O) and prostate carcinoma (PC-3) in mouse xenograft models associated with in vivo endothelial cell-specific apoptosis. The anti-angiogenic activity was localized to amino acids 54-132 using deletion mutagenesis. This anti-angiogenic region is separate from the 185-203 amino acid region responsible for the antitumor cell activity. Additionally, our experiments indicate that the antitumor cell activity is not realized until the peptide region is exposed by truncation of the alpha3(IV)NC1 domain, a requirement not essential for the anti-angiogenic activity of this domain. Collectively, these results effectively highlight the distinct and unique antitumor properties of the alpha3(IV)NC1 domain and the potential use of this molecule for inhibition of tumor growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
Koopman, G., Reutelingsperger, C., Kuijten, G., Keehnen, R., Pals, S., & van Oers, M. (1994) · Blood · doi:10.1182/blood.v84.5.1415.1415 · Cited by 2,681
Folkman, J., & Shing, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49853-0 · Cited by 2,654
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Caspases: Intracellular Signaling by Proteolysis
Salvesen, G. S., & Dixit, V. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80430-4 · Cited by 2,117
COLLAGENS: Molecular Biology, Diseases, and Potentials for Therapy
Prockop, D. J., & Kivirikko, K. I. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.002155 · Cited by 1,623
Cited by
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
Basement membranes: structure, assembly and role in tumour angiogenesis
Kalluri, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1094 · Cited by 1,748
Self-citationAngiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
Folkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Ascorbic acid: Chemistry, biology and the treatment of cancer
Du, J., Cullen, J. J., & Buettner, G. R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.06.003 · Cited by 1,070
TUMOR STROMA AND REGULATION OF CANCER DEVELOPMENT
Tlsty, T. D., & Coussens, L. M. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100224 · Cited by 987
Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis
Pepper, M. S. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.093685 · Cited by 777
Collagens and collagen-related diseases
Myllyharju, J., & Kivirikko, K. I. (2001) · Annals of Medicine · doi:10.3109/07853890109002055 · Cited by 756
Khoshnoodi, J., Pedchenko, V., & Hudson, B. G. (2008) · Microscopy Research and Technique · doi:10.1002/jemt.20564 · Cited by 668
Tumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
Hamano, Y., Zeisberg, M., Sugimoto, H., Lively, J. C., Maeshima, Y., Yang, C., Hynes, R. O., Werb, Z., Sudhakar, A., & Kalluri, R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00133-8 · Cited by 559
Self-citationEndogenous Inhibitors of Angiogenesis
Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 553
Self-citationSudhakar, A., Sugimoto, H., Yang, C., Lively, J., Zeisberg, M., & Kalluri, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730882100 · Cited by 488
Self-citationInteraction of endostatin with integrins implicated in angiogenesis
Rehn, M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.031564998 · Cited by 460
Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis
Maeshima, Y., Sudhakar, A., Lively, J. C., Ueki, K., Kharbanda, S., Kahn, C. R., Sonenberg, N., Hynes, R. O., & Kalluri, R. (2002) · Science · doi:10.1126/science.1065298 · Cited by 438
Self-citationVascular wall extracellular matrix proteins and vascular diseases
Xu, J., & Shi, G.-P. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.07.008 · Cited by 381
Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth
Barkan, D., Green, J. E., & Chambers, A. F. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.027 · Cited by 377
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia
Klein, G., Vellenga, E., Fraaije, M. W., Kamps, W. A., & de Bont, E. S. J. M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.001 · Cited by 350
Endogenous angiogenesis inhibitors
FOLKMAN, J. (2004) · APMIS · doi:10.1111/j.1600-0463.2004.apm11207-0809.x · Cited by 321
Three-dimensional context regulation of metastasis
Erler, J. T., & Weaver, V. M. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-008-9209-8 · Cited by 313
Cell Surface Glypicans Are Low-Affinity Endostatin Receptors
Karumanchi, S. A., Jha, V., Ramchandran, R., Karihaloo, A., Tsiokas, L., Chan, B., Dhanabal, M., Hanai, J.-I., Venkataraman, G., Shriver, Z., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00225-8 · Cited by 309
Self-citationRegulation of angiogenesis by extracellular matrix
Sottile, J. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2003.07.002 · Cited by 288
Adhesion events in angiogenesis
Eliceiri, B. P., & Cheresh, D. A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00252-0 · Cited by 287
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
Teodoro, J. G., Evans, S. K., & Green, M. R. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0221-2 · Cited by 260
Regulation of tumor angiogenesis by integrin-linked kinase (ILK)
Tan, C., Cruet-Hennequart, S., Troussard, A., Fazli, L., Costello, P., Sutton, K., Wheeler, J., Gleave, M., Sanghera, J., & Dedhar, S. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00281-2 · Cited by 260
Matricryptins and matrikines: biologically active fragments of the extracellular matrix
Ricard‐Blum, S., & Salza, R. (2014) · Experimental Dermatology · doi:10.1111/exd.12435 · Cited by 224
Endogenous inhibitors of angiogenesis
Ribatti, D. (2009) · Leukemia Research · doi:10.1016/j.leukres.2008.11.019 · Cited by 191
Sudhakar, A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24813 · Cited by 162
Retracted
Metadata
- Authors
- Maeshima, Y., Colorado, P. C., Torre, A., Holthaus, K. A., Grunkemeyer, J. A., Ericksen, M. B., Hopfer, H., Xiao, Y., Stillman, I. E., & Kalluri, R.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-07
- Volume
- 275
- Issue
- 28
- Pages
- 21340-21348
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2014696732
- Cited by
- 358
- References
- 47
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.